18.62 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||18.61 x 2200|
|Ask||21.95 x 900|
|Day's Range||17.50 - 19.14|
|52 Week Range||8.32 - 23.91|
|Beta (3Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.71|
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
REDWOOD CITY, Calif., Oct. 18, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that effective October 17, 2019, the compensation.
REDWOOD CITY, Calif., Oct. 15, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its third quarter 2019 financial results will.
Coherus Biosciences is the IBD Stock Of The Day as shares of the biotech company flirt with a breakout on expectations for a strong third quarter. Coherus makes biosimilars of branded drugs.
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Boosted by rebounding earnings and sales growth and a promising pipeline, biosimilars leader Coherus Biosciences is approaching a potential new buy.
REDWOOD CITY, Calif., Aug. 21, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare.
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 500.00% and 2.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
– Company is Profitable and Cash flow Positive from Operations for Second Quarter – – UDENYCA® is the Market Leading Pegfilgrastim Biosimilar with Approximately 13% Market Share.
REDWOOD CITY, Calif., July 29, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that the United States Court of Appeals for the.
Today we will run through one way of estimating the intrinsic value of Coherus BioSciences, Inc. (NASDAQ:CHRS) by...
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ expectations regarding the continued adoption of UDENYCA® in the U.S., estimation of channel mix, returns, chargebacks and rebates, each of which impact net sales computation. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made.
REDWOOD CITY, Calif., July 08, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its second quarter 2019 financial results will.
Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date. The cumulative production of 400,000 UDENYCA® pre-filled syringes is a significant milestone, as it represents approximately one-third of the annual utilization of pegfilgrastim in the United States. “Coherus provides unencumbered choice of pegfilgrastim product to patients and providers in the United States," said Denny Lanfear, President and CEO of Coherus.